|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the data of this study suggested that naringin presented anti-tumor effects in TC cells through inhibiting TC cell proliferation and inducing cell apoptosis via regulating the expression of cell proliferation and apoptosis related genes and PI3K/AKT pathway activation.
|
31727500 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, combined PI3K/mTOR and CDK4/6 inhibition is a highly promising novel approach for the treatment of aggressive, therapy-resistant thyroid cancer.
|
30699064 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions</b>: Our data demonstrate that vitamin C kills thyroid cancer cells by inhibiting MAPK/ERK and PI3K/AKT pathways via a ROS-dependent mechanism and suggest that pharmaceutical concentration of vitamin C has potential clinical use in thyroid cancer therapy.
|
31285773 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic alterations in pathways, including the mitogen‑activated protein kinase (MAPK)/extracellular signal‑regulated kinase (Erk) and phosphatidylinositol‑3‑kinase (PI3K)/protein kinase B (Akt) pathways, are the driving force behind the development of differentiated thyroid cancer cases into aggressive and undifferentiated forms of thyroid cancer.
|
30365150 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
|
31289610 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data showed that the c-Met/PI3K/Akt signaling pathway was responsible for the inhibitory effect of ING5 on the thyroid cancer.
|
29272787 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer.
|
29353884 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer.
|
29301825 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo.
|
29236327 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway.
|
29969438 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate a clear therapeutic potential of combining PLK1 and PI3K inhibitors in anaplastic thyroid tumors.
|
30243708 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to determine the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.<b>Experimental Design:</b> CUDC-907 is a first-in-class compound, functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway.
|
28600475 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, SGK1 was found to be essential for proliferation and survival of thyroid cancer cells harboring PI3K-activating mutations.
|
29055016 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanically, our data demonstrated that tumor-promoting role of N-cadherin in thyroid cancer was closely related to the activities of the MAPK/Erk, the phosphatidylinositol-3-kinase (PI3K)/Akt and p16/Rb signaling pathways in addition to affecting the EMT process.
|
28042956 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The initiation of thyroid cancer is often triggered by a genetic mutation in the phosphortidylinositol-3 kinase (PI3K) or mitogen-activated protein kinase (MAPK) pathway, such as <i>RAS</i> and <i>BRAF</i>, or by the rearrangement of growth factor receptor tyrosine kinase genes such as <i>RET/PTC</i>.
|
29163356 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
|
26456083 |
2016 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Demethylating the hypermethylated REC8 gene restored its expression in thyroid cancer cells in which the PI3K pathway was genetically over-activated and induced expression of REC8 protein inhibited the proliferation and colony formation of these cells.
|
26472282 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Treatment of the most resistant cell line, 8505c, using lexatumumab in combination with the BRAF(V600E) inhibitor, PLX4720, and the PI3K inhibitor, LY294002, (triple-drug combination) sensitizes the cells by triggering both the extrinsic and intrinsic apoptotic pathways in vitro as well as 8505c orthotopic thyroid tumors in vivo.
|
24603332 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.
|
24781864 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASAL1 displayed MAPK- and PI3K-suppressing and thyroid tumor-suppressing activities, which were all impaired by the mutations.
|
24136889 |
2013 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
These distinct genetic alterations constitutively activate the MAPK, PI3K and β-catenin signaling pathways, which have been implicated in thyroid cancer development and progression.
|
23128507 |
2013 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.
|
24098937 |
2013 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Initiation and progression of thyroid cancer involves multiple genetic and epigenetic alterations, of which mutations leading to the activation of the MAPK and PI3K-AKT signaling pathways are crucial.
|
21878896 |
2011 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates a genetic selectivity of MK2206 in inhibiting thyroid cancer cells by targeting the PI3K/Akt pathway, supporting a clinical trial in thyroid cancer.
|
21289267 |
2011 |